This makes them a viable option for reducing healthcare costs and improving access to essential medicines, particularly in countries like South Africa, where medication expenses constitute a significant part of the healthcare budget.
One of the most compelling benefits of generic drugs is their ability to improve access to treatment. Because they are sold at a fraction of the price of branded drugs, patients can afford medications that were previously out of reach, and healthcare systems can allocate their resources more efficiently.
The lower cost of generics is primarily due to their reduced research, development, and marketing expenses. Once the patent for a branded drug expires, generic manufacturers can replicate the drug, leading to competition that drives down prices.
In some cases, the entry of generic versions into the market has resulted in price drops of up to 60% for branded drugs. This makes generics an indispensable tool for managing healthcare costs, especially in low- and middle-income countries.
In South Africa, legislation like Act 90 promotes the use of generics by mandating substitution at pharmacies, ensuring patients have access to more cost-effective treatments. These savings can be reinvested in new technologies or treatments, enhancing the sustainability of healthcare systems.
Regulatory authorities such as the South African Health Products Regulatory Authority, the American Food and Drug Administration, and the European Medicines Agency play a crucial role in ensuring that both branded and generic medicines meet international standards for quality, safety, and efficacy.
These bodies enforce compliance with good manufacturing practices by conducting audits and inspections of manufacturing facilities to ensure that they meet required standards. Additionally, post-marketing activities, such as random product testing and monitoring for adverse drug reactions, help maintain the safety of generic drugs in the market.
The approval process for generic drugs differs from that of branded medicines. While branded drugs undergo extensive clinical trials to demonstrate safety and efficacy, generic drugs must only prove bioequivalence. Bioequivalence means that the generic product has the same active ingredients, strength, dosage form, and route of administration as the branded drug, and it works in the same way within the body. This is determined by assessing bioavailability - the rate and extent to which the active ingredient reaches systemic circulation.
In cases where excipients (inactive ingredients) differ between branded and generic drugs, adverse reactions may occur, particularly among patients with sensitivities to certain substances, such as lactose. It is essential to examine the professional information leaflet and report any adverse events to ensure patient safety.
Special attention is required for elderly patients and those with cognitive impairments or those on multiple medications (polypharmacy), as generic substitutions can lead to confusion, dose duplication, and other risks. Educating patients about their medications and ensuring clear communication between healthcare providers and pharmacists are critical steps in preventing such issues.
Bioequivalence studies are typically conducted using a single-dose, two-period crossover design in healthy volunteers. The goal is to compare the pharmacokinetic profiles of the generic and branded drugs, focusing on parameters like the area under the curve and peak concentration. A 90% confidence interval within a logarithmic range of 80%-125% is required for approval, ensuring that any differences in drug exposure are minimal and do not affect the drug’s effectiveness.
For narrow therapeutic index drugs (NTI), such as warfarin or immunosuppressants, small variations in drug levels can have significant safety implications. However, studies have shown that with proper monitoring, generic NTI drugs can be safely substituted for their branded counterparts.
To watch a replay of the webinar, click here.
